Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $32.00

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has been given an average rating of “Moderate Buy” by the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $32.00.

A number of equities analysts have issued reports on the company. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. HC Wainwright lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $35.00 to $31.50 in a research note on Thursday, May 28th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Stephens set a $32.00 price target on Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Finally, Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $31.36 on Wednesday. The stock has a fifty day moving average price of $29.16 and a two-hundred day moving average price of $25.63. The firm has a market cap of $3.84 billion, a P/E ratio of 18.02, a PEG ratio of 0.95 and a beta of 0.74. Catalyst Pharmaceuticals has a 1 year low of $19.05 and a 1 year high of $32.56.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rothschild Investment LLC boosted its stake in shares of Catalyst Pharmaceuticals by 1,085.7% during the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,520 shares in the last quarter. Advisory Services Network LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter worth $39,000. Quarry LP bought a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter worth $40,000. Clearstead Advisors LLC boosted its stake in shares of Catalyst Pharmaceuticals by 192.9% during the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 1,167 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Catalyst Pharmaceuticals by 55.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 630 shares in the last quarter. 79.22% of the stock is owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).